IceCure Medical Ltd
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Eyal Shamir
- Full Time Employees
- 69
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 7 Ha’Eshel Street Caesarea HA Israel 3079504
- IPO Date
- Aug 26, 2021
- CIK
- 0001584371
- Website
- icecure-medical.com
- Similar Companies
- Business
- IceCure Medical Ltd (Nasdaq: ICCM), a commercial-stage medical device company founded in 2006 and headquartered in Caesarea, Israel, researches, develops, and markets liquid nitrogen-based cryoablation systems, disposables, and technologies for the minimally invasive treatment of benign and malignant tumors in women's health and interventional oncology. The company offers the ProSense system, a single-probe cryoablation platform using liquid nitrogen to generate ultra-cold temperatures for creating large lethal zones in tumors such as malignant breast tumors (FDA-cleared in October 2025 for patients aged 70+ with low-risk tumors ≤1.5 cm treated with endocrine therapy), kidney, lung, liver, and bone cancers; the IceSense3 system for ablation across urology (prostate cancer, BPH), oncology, dermatology (skin cancers, warts), gynecology, general surgery (breast fibroadenomas), thoracic surgery, ENT, proctology (hemorrhoids, pilonidal cysts), and palliative care; and developmental-stage systems including XSense (single-probe) and MultiSense (multi-probe for larger tumors). IceCure operates in the United States, Europe (including recent regulatory approval for ProSense in Switzerland covering breast, lung, liver, and kidney indications), Japan (via partner Terumo Corporation, with regulatory submission planned for H1 2026), Israel, India, China, and other international markets, targeting physicians in interventional radiology, oncology, urology, and surgery for office-based and CT-guided procedures. Recent developments include FDA marketing authorization for ProSense in early-stage low-risk breast cancer in October 2025, promotion of Shay Levav to Chief Operating Officer in November 2025 to support U.S. commercial scaling to 30 sites, closure of a $10 million over-subscribed rights offering in August 2025, submission of next-generation XSense to Israeli regulators, positive interim ICESECRET kidney study results (88.7% recurrence-free rate for tumors ≤3 cm presented in March 2025), and ongoing post-market study protocols with the FDA.
IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation
IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer
IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor
IceCure Stock Surges After 70% ProSense Install Increase
IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance
IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance
IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked
IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript
IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates
IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America
IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026
IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market
IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025
Reviewing IceCure Medical (NASDAQ:ICCM) and Pediatrix Medical Group (NYSE:MD)
Head-To-Head Analysis: Biocorrx (OTCMKTS:BICX) and IceCure Medical (NASDAQ:ICCM)
IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement
IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates